TRANS  RADEME  (to be used for all corre	O		Application Numbe	ŗ	10/658,348		
TRAN	SMITTAL	•	Filing Date		September 8, 2003		
RADEME FO	ORM		First Named Invent	or	Stephen D. Pacetti		
(to be used for all corre	espondence after in	nitial filing)	Group Art Unit		3738		
			Examiner Name		Hieu Phan		
Total Number of Pages	in This Submission	14	Attorney Docket No	umber	50623.332		
		ENCLO	OSURES (check all that a	apply)			
Deposit Account 07 Authorization	7-1850		f Assignment Papers (co & documents)	ver	After Allowance Communication Group		
2 Postage Paid Re	turn Postcards	Formal	Drawings		Appeal Communication to Board Appeals and Interferences		
Preliminary Amend	ment	Specific			Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)		
Fee Transmittal (in	duplicate)	Transm	st for Continued Examina nittal (RCE)	^	Proprietary Information		
Utility Patent Applic	cation Transmittal	Fee Ira	ansmittal Form (in duplic	ate)	Status Letter		
Copy of Combined Power of Attorney			of Attorney, Revocation e of Correspondence Ado	dress	Other Enclosure(s) (please identify below):		
Information Disclos		Termin	al Disclaimer				
and 290 Reference		Reques	Request for Refund				
Express Mail Label	No.	CD, Nu	imber of CD(s)				
Certified Copy of P Document(s)	riority	Rema	rks				
Response to Missir Incomplete Applica	•						
Response to M Parts under 37 1.52 or 1.53							
	SIGNA	TURE OF A	APPLICANT, ATTOR	NEY, OF	R AGENT		
	Squire, Sanders & Paul J. Meyer, Jr.,						
Signature	12						
Date	December 20	03					
	<u> </u>	CEI	RTIFICATE OF MAILI	NG			
I hereby certify that this	correspondence i	s being depo	sited with the United Stat	tes Posta	al Service as first class mail in an enve		
, ,					on this date: December <u>31</u> , 2003		
Typed or printed name		•					
Typed of printed fiallie	Diluaniadua	u					

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be send to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Attorney Docket No.:50623.332

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Examiner:

Hieu Phan

Stephen D. Pacetti et al.

Serial No.:

10/658,348

Art Unit:

3738

Filed:

September 8, 2003

Title:

A Method of Forming A Diffusion Barrier Layer for Implantable Devices

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§1.97-1.98

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicants hereby notify the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. According to a Notice signed July 11, 2003, the U.S. Patent and Trademark Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for all patent applications filed after June 30, 2003. *See*, 1276 Off. Gaz. Pat. Office 55. Since this patent application was filed after June 30, 2003, Applicants have not provided copies of the cited U.S. patents or the U.S. Patent Application Publications. Copies of the cited foreign patent documents and non-patent literature have been submitted herewith.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicants reserve the right to dispute any of the listed documents as prior art during examination. Furthermore, Applicants do not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.

The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: December 30, 2003 Squire, Sanders & Dempsey L.L.P. One Maritime Plaza, Suite 300 San Francisco, CA 94111 Telephone (415) 954-0200 Facsimile (415) 393-9887

Respectfully submitted,

Paul J. Meyer, Jr. Attorney for Applicants Reg. No. 47,791 FORM PTO-1449 (Modified) US DE Approved 優r USE through 10/31/2002 US I

JAN O 5 2004

US DEPARTMENT OF COMMERCE
US Patent and Trademark Office

Docket No. 50623.332

Application No. 10/658,348

INFORMATION DISCLOSURE CITATION Applicant

in an Application

(Use several sheets if necessary)

Stephen D. Pacetti et al.

Filing Date

Group Art Unit 3738

September 8, 2003

APENT &	RADEMA		U.S. PATE	ENT DOCUMENTS			
Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,329,383	5/11/82	Joh	428	36	
	A2	4,733,665	3/29/88	Palmaz	128	343	
	A3	4,800,882	1/31/89	Gianturco	128	343	
	A4	4,882,168	11/21/89	Casey et al.	424	468	
	A5	4,886,062	12/12/89	Wiktor	128	343	
· · ·	A6	4,941,870	7/17/90	Okada et al.	600	36	
	A7	4,977,901	12/18/90	Ofstead	128	772	
	A8	5,064,435	11/12/91	Porter	623	12	
<u> </u>	A9	5,071,407	12/10/91	Termin et al.	604	104	
	A10	5,078,736	1/7/92	Behl	623	1	
	A11	5,092,841	3/3/92	Spears	604	96	
-	A12	5,112,457	5/12/92	Marchant	204	165	
	A13	5,165,919	11/24/92	Sasaki et al.	424	488	
	A14	5,272,012	12/21/93	Opolski	428	423.1	
	A15	5,292,516	3/8/94	Viegas et al.	424	423	
	A16	5,298,260	3/29/94	Viegas et al.	424	486	
	A17	5,300,295	4/5/94	Viegas et al.	424	427	
	A18	5,306,501	4/26/94	Viegas et al.	424	423	
	A19	5,328,471	7/12/94	Slepian	604	101	-
,	A20	5,330,768	7/19/94	Park et al.	424	501	
	A21	5,344,411	9/6/94	Domb et al.	604	265	
	A22	5,344,425	9/6/94	Sawyer	606	198	
	A23	5,380,299	1/10/95	Fearnot et al.	604	265	
	A24	5,417,981	5/23/95	Endo et al.	424	486	
	A25	5,447,724	9/5/95	Helmus et al.	424	426	
	A26	5,455,040	10/3/95	Marchant	424	426	

	<u> ,  0 ,</u>	JAN 6 3 250 E					
	A270	5,462,990 FRADENIA	10/31/95	Hubbell et al.	525	54.1	
	A28	5,464,650	11/7/95	Berg et al.	427	2.30	
	A29	5,474,089	12/12/95	Waynant	128	843	
	A30	5,569,463	10/29/96	Helmus et al.	424	426	
	A31	5,571,086	11/5/96	Kaplan et al.	604	96	
_	A32	5,576,072	11/19/96	Hostettler et al.	427	532	
	A33	5,578,073	11/26/96	Haimovich et al.	623	1	
	A34	5,605,696	2/25/97	Eury et al.	424	423	
	A35	5,609,629	3/11/97	Fearnot et al.	623	1	
	A36	5,624,411	4/29/97	Tuch	604	265	
	A37	5,628,730	5/13/97	Shapland et al.	604	21	
	A38	5,628,730	5/13/97	Shapland et al.	604	21	
	A39	5,649,977	7/22/97	Campbell	623	1	
	A40	5,658,995	8/19/97	Kohn et al.	525	432	
·	A41	5,662,960	9/2/97	Hostettler et al.	427	2.3	
	A42	5,667,767	9/16/97	Greff et al.	424	9.411	
	A43	5,670,558	9/23/97	Onishi et al.	523	112	
	A44	5,676,685	10/14/97	Razavi	606	194	
	A45	5,679,400	10/21/97	Tuch	427	2.14	
	A46	5,700,286	12/23/97	Tartaglia et al.	623	1	
	A47	5,702,754	12/30/97	Zhong	427	2.12	
	A48	5,716,981	2/10/98	Hunter et al.	514	449	
	A49	5,728,152	3/17/98	Mirsch, II et al.	623	2	
	A50	5,735,897	4/7/98	Buirge	623	12	
	A51	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	A52	5,762,638	6/9/98	Shikani et al.	604	265	
	A53	5,776,184	7/7/98	Tuch	623	1	
	A54	5,788,979	8/4/98	Alt et al.	424	426	
	A55	5,792,550	8/11/98	Phillips et al.	428	336	
	A56	5,800,392	9/1/98	Racchini	604	96	
	A57	5,820,917	10/13/98	Tuch	427	2.1	
	A58	5,824,048	10/20/98	Tuch	623	.1	

	JAN 0 5 ZOUM ES					
A5	9 5,824,048	10/20/98	Ragheb et al.	623	1	
A6	9 5,824,048 0 5,824,048 0 5,030,178	11/3/98	Jones et al.	604	49	
A6	1 5,830,430	11/3/98	Unger et al.	424	1.21	
A6	2 5,837,008	11/17/98	Berg et al.	623	1	
A6	3 5,837,313	11/17/98	Ding et al.	427	2.21	
A6	4 5,843,156	12/1/98	Slepian et al.	623	1	
A6	5 5,849,035	12/15/98	Pathak et al.	623	1	
A6	6 5,849,368	12/15/98	Hostettler et al.	427	536	
A6	7 5,851,508	12/22/98	Greff et al.	424	9.411	
A6	8 5,854,382	12/29/98	Loomis	528	354	
A6	9 5,855,563	1/5/99	, Kaplan et al.	604	49	
A7	0 5,855,599	1/5/99	Wan	623	1	
A7	1 5,858,746	1/12/99	Hubbell et al.	435	177	
A7:	5,858,990	1/12/99	Walsh	514	44	
A7	3 5,865,814	2/2/99	Tuch	604	265	
A7-	5,869,127	2/9/99	Zhong	427	2.12	
A7	5 5,873,904	2/23/99	Ragheb et al.	623	1	
A7	5,876,433	3/2/99	Lunn	623	1	
A7	7 5,877,224	3/2/99	Brocchini et al.	514	772.2	
A7	5,895,420	4/20/99	Mirsch, II et al.	623	2	
A7	5,898,066	4/27/99	Benowitz et al.	530	300	
A8	5,899,935	5/4/99	Ding	623	1	
A8	5,911,702	6/15/99	Romley et al.	604	53	
A8:	5,919,570	7/6/99	Hostettler et al.	428	424.8	
A8:	5,925,720	7/20/99	Kataoka et al.	525	523	
A8-	5,951,458	9/14/99	Hastings et al.	600	3	
A8:	5 5,955,509	9/21/99	Webber et al.	514	772.7	
A80	5,961,547	10/5/99	Razavi	623	1	
A8 <sup>-</sup>	7 5,971,954	10/26/99	Conway et al.	604	96	
A8	5,980,928	11/9/99	Terry	424	427	<u> </u>
A89	5,980,972	11/9/99	Ding	427	2.24	
A90	5,997,517	12/7/99	Whitbourne	604	265	
A9	6,005,020	12/21/99	Loomis	523	105	

•	*	JAN 0 3 Lot 3					
•	A92	JAN 9 5.55 5.55 5.55 5.55 5.55 5.55 5.55 5	1/4/00	Goicoechea	623	1	2/18/98
	A93	6,013,780	1/11/00	Neufeld et al.	536	23.1	1/21/97
	A94	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A95	6,017,577	1/25/00	Hostettler et al.	427	2.12	2/1/95
	A96	6,022,901	2/8/00	Goodman	514	733	5/13/98
	A97	6,026,316	2/15/00	Kucharczyk et al.	600	420	5/15/97
	A98	6,028,164	2/22/00	Loomis	528	354	2/1/99
	A99	6,030,656	2/29/00	Hostettler et al.	427	2.3	3/24/98
	A100	6,033,582	3/7/00	Lee et al.	216	37	1/16/98
	A101	6,040,058	3/21/00	Hostettler et al.	428	457	8/27/98
	A102	6,042,875	3/28/00	Ding et al.	427	2.24	3/2/99
	A103	6,051,648	4/18/00	Rhee et al.	525	54.1	1/13/99
	A104	6,051,576	4/18/00	Ashton et al.	514	255	1/29/97
	A105	6,056,993	5/2/00	Leidner et al.	427	2.25	4/17/98
	A106	6,056,938	5/2/00	Unger et al.	424	1.21	5/5/98
	A107	6,060,451	5/9/00	DiMaio et al.	514	13	3/20/95
	A108	6,060,518	5/9/00	Kabanov et al	514	781	8/16/96
	A109	6,061,587	5/9/00	Kucharczyk et al.	600	411	5/15/97
	A110	6,080,488	6/27/00	Hostettler et al.	428	423.3	3/24/98
	A111	6,086,773	7/11/00	Dufresne et al.	216	8	5/22/98
	A112	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A113	6,096,726	8/1/00	Opolski	514	53	3/11/98
	A114	6,099,562	8/8/00	Ding et al.	623	1.46	12/22/97
	A115	6,102,046	8/15/00	Weinstein et al.	128	898	6/2/98
,	A116	6,110,188	8/29/00	Narciso, Jr.	606	153	3/9/98
	A117	6,110,483	8/29/00	Whitbourne et al.	424	423	6/23/97
	A118	6,113,629	9/5/00	Ken	623	1.1	5/1/98
	A119	6,120,536	9/19/00	Ding et al.	623	1.43	6/13/96
	A120	6,120,904	9/19/00	Hostettler et al.	428	423.3	5/24/99
	A121	6,121,027	9/19/00	Clapper et al.	435	180	8/15/97
	A122	6,126,649	10/3/00	VanTassel et al.	604	528	6/10/99
	A123	6,129,761	10/10/00	Hubbell	623	11	6/7/95
	A124	6,136,006	10/24/00	Johnson et al.	606	108	7/27/98

•	(	IAM O 5 WAY S					
	4125	6,140,462 6,140,462 6,153,252	10/31/00	Felt et al.	528	60	11/18/98
	4126	BADE 1133,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	4127	6,156,064	12/5/00	Chouinard	623	1.44	8/14/98
	4128	6,156,350	12/5/00	- Constantz	424	666	12/2/99
	4129	6,159,232	12/12/00	Nowakowski	606	213	12/15/98
	4130	6,162,244	12/19/00	Braun et al.	623	1.12	9/23/98
	4131	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99
	4132	6,178,346	1/23/01	Amundson et al.	600	473	10/23/98
	4133	6,179,817	1/30/01	Zhong	604	265	1/28/99
	4134	6,183,469	2/6/01	Thapliyal et al.	606	41	1/2/98
	4135	6,197,051	3/6/01	Zhong	623	1.46	2/11/99
	A136	6,203,551	3/20/01	Wu	606	108	10/4/99
	4137	6,211,247	4/3/01	Goodman	514	733	11/4/99
	A138	6,231,600	5/15/01	Zhong	623	1.42	5/26/99
	4139	6,238,364	5/29/01	Becker	604	8	2/9/00
	4140	6,240,616	6/5/01	Yan	29	527.2	4/15/97
,	<b>A141</b>	6,245,753	6/12/01	Byun et al.	514	56	4/27/99
	<b>A142</b>	6,251,136	6/26/01	Guruwaiya et al.	623	1.46	12/8/99
	4143	6,249,952	6/26/01	Ding	29	460	3/8/99
	4144	6,254,632	7/3/01	Wu et al.	623	1.15	9/28/00
	A145	6,254,634	7/3/01	Anderson et al.	623	1.42	6/10/98
	A146	6,258,121	7/10/01	Yang et al.	623	1.46	7/2/99
	<b>A147</b>	6,261,320	7/17/01	Tam et al.	623	1.15	2/19/99
	<b>A148</b>	6,265,016	7/24/01	Hostettler et al.	427	2.11	3/21/00
	4149	6,265,199	7/24/01	Sheppard et al.	435	212	7/9/99
	<b>A150</b>	6,274,164	8/14/01	Novich	424	443	9/15/00
	A151	6,283,947	9/4/01	Mirzaee	604	264	7/13/99
	A152	6,283,949	9/4/01	Roorda	604	288.02	12/27/99
	A153	6,284,305	9/4/01	Ding et al.	427	2.28	5/18/00
	<b>A154</b>	6,283,951	9/4/01	Flaherty et al.	604	529	3/25/98
-	A155	6,287,628	9/11/01	Hossainy et al.	427	2.3	9/3/99

•		M 0 5 2004 25			<del></del> -	, , ,	<del></del>
,	A (56)	6,287,249	9/11/01	Tam et al.	600	3	2/19/99
	A157	7 € TR® 950,729	9/18/01	Slepian et al.	623	23.72	12/3/97
	A158	6,299,604	10/9/01	Ragheb et al.	604	265	8/20/99
	A159	6,302,875	10/16/01	Makower et al.	604	528	4/11/97
	A160	6,306,176	10/23/01	Whitbourne	623	23.59	9/21/99
	A161	6,306,177	10/23/01	Felt et al.	623	23.6	12/18/97
	A162	6,316,522	11/13/01	Loomis et al.	523	105	9/14/99
	A163	6,322,771	11/27/01	Linden et al.	424	9.3	6/18/99
	A164	6,331,313	12/18/01	Wong et al.	424	427	10/22/99
	A165	6,335,029	1/1/02	Kamath et al.	424	423	12/3/98
	A166	6,334,867	1/1/02	Anson	623	1.13	3/6/98
	A167	6,346,110	2/12/02	Wu	606	108	1/3/01
	A168	6,358,556	3/19/02	Ding et al.	427	2.24	1/23/98
	A169	6,379,381	4/30/02	Hossainy et al.	623	1.42	9/3/99
	A170	6,395,326	5/28/02	Castro et al.	427	2.24	5/31/00
	A171	6,391,052	5/02	Buirge	204	499	10/29/97
	A172	6,410,044	6/02	Chudzik	424	423	5/16/00
	A173	6,419,692	7/16/02	Yang et al.	623	1.15	2/3/99
	A174	6,451,373	9/17/02	Hossainy et al.	427	2.25	8/4/00
	A175	6,494,862	12/17/02	Ray et al.	604	96.01	12/30/99
	A176	6,503,556	1/7/03	Harish et al.	427	2.24	12/28/00
	A177	6,503,954	1/7/03	Bhat et al.	514	772.2	7/21/00
	A178	6,506,437	1/14/03	Harish et al.	427	2.25	10/17/00
	A179	6,527,801	3/4/03	Dutta	623	1.46	4/13/00
	A180	6,527,863	3/4/03	Pacetti et al.	118	500	6/29/01
	A181	6,540,776	4/1/03	Sanders Millare et al.	623	1.15	12/28/00
	A182	6,544,223	4/8/03	Kokish	604	103.01	1/5/01
	A183	6,544,543	4/8/03	Mandrusov et al.	424	422	12/27/00
	A184	6,544,582	4/8/03	Yoe	427	2.24	1/5/01
	A185	6,555,157	4/29/03	Hossainy	427	2.24	7/25/00

•		JAN 0 5 2004	<u></u>					
	A186	558,733 6 565 659	5/6/03	Hossainy et al.	427	2.24	10/2	6/00
	A187	6,565,659	5/20/03	Pacetti et al.	118	500	6/28	3/01
	A188	6,572,644	6/3/03	Moein	623	1.11	6/27	7/01
	A189	6,585,765	7/1/03	Hossainy et al.	623	1.45	6/29	9/00
	A190	6,585,926	7/1/03	Mirzaee	264	400	8/31	1/00
	A191	6,605,154	8/12/03	Villareal	118	500	5/3	1/01
···········	A192	09/676,049		Castro et al.			9/28	8/00
	A193	09/750,595		Hossainy et al.			12/2	8/00
		U.S. PATE	NT APPLICAT	ON PUBLICATION DOCU	MENTS	J		
Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	, ,	Date if
	A194	2001/0018469	8/30/01	Chen et al.	523	121	12/2	8/00
	A195	2001/0037145	11/1/01	Guruwaiya et al.	623	1.15	6/21	1/01
	A196	2002/0077693	6/20/02	Barclay et al.	623	1.13	12/1	9/00
	A197	2002/0091433	7/11/02	Ding et al.	623	1.2	12/1	7/01
	A198	2002/0155212	10/24/02	Hossainy	427	2.25	4/24	1/01
	A199	2003/0065377	4/3/03	Davila et al.	623	1.13	4/30	0/02
	A200	2003/0099712	5/29/03	Jayaraman	424	486	11/2	6/01
	<del></del>		FOREIGN PA	ATENT DOCUMENTS				
Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Trans Yes	lation No
	B1	EP 0 301 856	2/1/89	European				
	B2	EP 0 514 406	11/25/92	European				
	В3	EP 0 604 022	6/29/94	European				
	B4	EP 0 623 354	11/9/94	European				<u> </u>
	B5	EP 0 665 023	8/2/95	European				
	В6	EP 0 701 802	3/20/96	European				
	В7	EP 0 716 836	6/19/96	European				
	В8	EP 0 809 999	12/3/97	European		ļ		
	В9	EP 0 832 655	4/1/98	European				ļ
	B10	EP 0 850 651	7/1/98	European				
	B11	EP 0 879 595	11/25/98	European				-
	B12	EP 0 910 584	4/28/99	European				
	B13	EP 0 923 953	6/23/99	European				

	\ <b>3</b> ¢*			 
, B14	4 EP 8 2508 895 MR	11/3/99	European	
B1:	EP 0 970 711	1/12/00	European	
B16	6 EP 0 982 041	3/1/00	European	
B17	7 EP 1 273 314	1/8/03	European	
B18	3 2001-190687	7/17/01	Japan (Abstract)	Χ.
B19	WO 91/12846	9/5/91	PCT	
B20	WO 95/10989	4/27/95	PCT	
B2 <sup>-</sup>	WO 96/40174	12/19/96	PCT	
B22	WO 97/10011	3/20/97	PCT	
B2:	3 WO 97/45105	12/4/97	PCT	
B24	WO 97/46590	12/11/97	PCT	
B25	5 WO 98/17331	4/30/98	PCT	
B26	WO 98/36784	8/27/98	PCT	,
B27	7 WO 99/01118	1/14/99	PCT	
B28	3 WO 99/38546	8/5/99	PCT	
B29	WO 99/63981	12/16/99	PCT	
B30	WO 00/02599	1/20/00	PCT	
B3 <sup>-</sup>	WO 00/12147	3/9/00	PCT	
B32	2 WO 00/18446	4/6/00	PCT	
B33	WO 00/64506	11/2/00	PCT	
B34	WO 01/01890	1/11/01	PCT	
B35	WO 01/15751	3/8/01	PCT	
B36	WO 01/17577	3/15/01	PCT	
B37	WO 01/45763	6/28/01	PCT	
B38	3 WO 01/49338	7/12/01	PCT	
B39	WO 01/74414	10/11/01	PCT	
B40	WO 02/03890	1/17/02	PCT	
B4 <sup>-</sup>	WO 02/026162	4/4/02	PCT	
B42	2 WO 02/34311	5/2/02	PCT	
B43	WO 02/056790	7/25/02	PCT	
B44	WO 03/000308	1/3/03	PCT	

	144022	<b></b>		<u></u>				
 B45	WO 03/022323	3/20/03	PCT					
 B46	WO 03/028780	4/10/03	PCT		ļ			
B47	WO 03/037223	5/8/03	PCT					
B48	WO 03/039612	5/15/03	PCT			<u></u>		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)								
C1		nonymous, Cardiologists Draw - Up The Dream Stent, Clinica 710:15 (June 17, 1996), http://www.dialogweb.com/cgi/document?req=1061848202959, printed 8/25/03 (2 pages).						
C2		nonymous, <i>Heparin-coated stents cut complications by 30%</i> , Clinica 732:17 (Nov. 18, 1996), ttp://www.dialogweb.com/cgi/document?req=1061847871753, printed 8/25/03 (2 pages).						
 СЗ		Anonymous, Rolling Therapeutic Agent Loading Device for Therapeutic Agent Delivery or Coated Stent Abstract 434009), Res. Disclos. pp. 974-975 (June 2000).						
C4			ninate cardiology, Clinica 720:22 nt?req=1061848017752, printed					
C5	Aoyagi et al., <i>Prepara</i> Journal of Controlled		ed aliphatic polyester and applic 5 (1994).	ation to ther	mo-respo	nsive ma	aterial,	
C6			tocatalytic Deposition of Palladi , printed December 12, 2003 (4					
 C7	Barath et al., Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury, JACC 13(2): 252A (Abstract) (Feb. 1989).							
C8	Barbucci et al., Coating of commercially available materials with a new heparinizable material, J. Biomed. Mater. Res. 25:1259-1274 (Oct. 1991).							
С9	Baudrand et al., Elect	roless Palladium, Electroplaters an	Past and Future, Proceedings of Surface Finishers Society, 19	of the AESF 99, pp. 49-5	annual te	chnical		
C10			ne: Modern Plastics Internation nt 2000 FT Asia Intelligence Wil				ies	
C11	Chung et al., <i>Inner co</i> Journal of Controlled		n for drug delivery control of the 3 (2000)	ermo-respon	sive polyr	meric mi	celles,	
C12			the Arterial Wall Via Polyuretha. neterization and Cardiovascular					
C13	Dichek et al., Seeding 80(5):1347-1353 (Nov		Stents with Genetically Enginee	red Endothe	elial Cells,	Circ.		
C14	DNP Products & Serv	ices – Packaging nternational/pack/	, "Barrier Carton for Liquid L-Ca carton/carton 1.html, printed D	rton L-Barrie ecember 30	er L-Alum , 2003 (1	i," page).		
C15			, "Barrier Carton for Liquid L-Ca (carton/carton 2.html, printed D					
C16	DNP Products & Serv	ices – Packaging nternational/pack/	, "Barrier Carton for Liquid L-Ca carton/carton_3.html, printed D	rton L-Barrie ecember 10	er L-Alum , 2003 (1	i," page).		
C17	Eigler et al., Local Art	erial Wall Drug De	elivery from a Polymer Coated I a, JACC, 4A (701-1), Abstract (I	Removable I			etics,	
C18	Electro-Coatings of lo	wa, Inc., "Kaniger	n® Electroless Nickel Alloy," rocoatings/kantech.htm, printed		30, 2003 <sub>'</sub>	(3 pages	š).	
C19	Erlat et al., Morpholog With Plasma-Enhance pp. 704-717	ny And Gas Barrie ed Chemical Vapo	er Properties Of Thin SiO <sub>x</sub> Coati or Deposition Conditions, J. Mat	ngs On Poly er. Res., Vo	<i>carbonate</i> I. 15, No.	e: Correl 3, Mar.:	ations 2000,	
C20	- <del>                                    </del>	Biomedical Mater	ials, MRS Bulletin, pp. 33-38 (S	ept. 1991).				

	JAN S
C21	Herdeg et a., Antiprohierative Stent Coatings: Taxol and Related Compounds, Semin. Intervent. Cardiol. 3:197-199 (1998) RADIO CONTRACTOR (1998) RADIO
C22	Inoue et al., An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs, Journal of Controlled Release 51:221-229 (1998).
C23	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).
C24	Levy et al., Strategies For Treating Arterial Restenosis Using Polymeric Controlled Release Implants, Biotechnol. Bioact. Polym. [Proc. Am. Chem. Soc. Symp.], pp. 259-268 (1994).
C25	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).
C26	Marconi et al., Covalent bonding of heparin to a vinyl copolymer for biomedical applications, Biomaterials 18(12):885-890 (1997).
C27	Matsumaru et al., Embolic Materials For Endovascular Treatment of Cerebral Lesions, J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).
C28	Mitsubishi Chemical Kohjin PAX Corporation, "Transparent Excellent Gas Barrier Plastic Film TECHBARRIER®," <a href="http://www.techbarrier.com/techbarrier/index.htm">http://www.techbarrier.com/techbarrier/index.htm</a> , printed December 10, 2003 (3 pages).
C29	Mitsubishi Chemical Kohjin PAX Corporation, "TECHBARRIER®-S," <a href="http://www.techbarrier.com/techbarrier/tech-s.htm">http://www.techbarrier.com/techbarrier/tech-s.htm</a> , printed December 30, 2003 (2 pages).
C30	Mitsubishi Chemical Kohjin PAX Corporation, "How to Handle and Convert TECHBARRIER®," <a href="http://www.techbarrier.com/techbarrier/tech-kakou.htm">http://www.techbarrier.com/techbarrier/tech-kakou.htm</a> , printed December 10, 2003 (2 pages).
C31	Miyazaki et al., Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice, Chem. Pharm. Bull. 33(6) 2490-2498 (1985).
C32	Miyazawa et al., Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat, J. Cardiovasc. Pharmacol., pp. 157-162 (1997).
C33	Nordrehaug et al., <i>A novel biocompatible coating applied to coronary stents</i> , European Heart Journal 14, p. 321 (P1694), Abstr. Suppl. (1993).
C34	Ohsawa et al., Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty, American Heart Journal 136(6):1081-1087 (Dec. 1998).
C35	Ozaki et al., <i>New Stent Technologies</i> , Progress in Cardiovascular Diseases, Vol. XXXIX(2):129-140 (Sept./Oct. 1996).
C36	Pharmaceutical & Medical Packaging News, "Film Preserves Blood Substitute," <a href="http://www.devicelink.com/grabber.php3?URL=http:www.devicelink.com/pmpn/achive">http://www.devicelink.com/grabber.php3?URL=http:www.devicelink.com/pmpn/achive</a> , printed December 10, 2003 (3 pages).
C37	Pechar et al., Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin, Bioconjucate Chemistry 11(2):131-139 (Mar./Apr. 2000).
C38	Peng et al., Role of polymers in improving the results of stenting in coronary arteries, Biomaterials 17:685-694 (1996).
C39	Shigeno, Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor, Chemical Abstract 125:212307 (1996).
C40	van Beusekom et al., Coronary stent coatings, Coronary Artery Disease 5(7):590-596 (July 1994).
C41	Wilensky et al., <i>Methods and Devices for Local Drug Delivery in Coronary and Peripheral Arteries</i> , Trends Cardiovasc. Med. 3(5):163-170 (1993).
C42	Yokoyama et al., Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor, Journal of Controlled Release 50:79-92 (1998).

JAN 0 5 2004 3

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.